1887

Abstract

It is well known that carbapenem-resistant mutations in penicillin-binding proteins (PBPs) are not observed in most Gram-negative bacteria under either clinical or experimental conditions. To understand the mechanisms involved in carbapenem resistance, this study constructed a - and -deficient strain, which was expected to have elevated mutation frequencies and to lack drug efflux. Using this mutant, carbapenem-resistant strains with target mutations were successfully and efficiently isolated. The mutations T547I/A, M574I and G601D were identified in the PBP2 gene. Meropenem (MEPM)-resistant strains with the PBP2 T547I mutation showed fourfold increased resistance to 1-β-methyl-substituted carbapenems, such as doripenem, MEPM and biapenem, but not to non-substituted carbapenems such as imipenem and panipenem and other β-lactams. In addition, resistance resulting from the G601D mutation was limited to MEPM, whilst the M574I mutation conferred resistance to MEPM, imipenem and panipenem. This is the first report, to the best of our knowledge, that also has a carbapenem-resistance mechanism as a result of PBP2 mutations, and it provides insight into the resistance profiles of PBP2 mutations to carbapenems with and without the 1-β-methyl group.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.051631-0
2013-03-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/3/429.html?itemId=/content/journal/jmm/10.1099/jmm.0.051631-0&mimeType=html&fmt=ahah

References

  1. Asahi Y., Takeuchi Y., Ubukata K. 1999; Diversity of substitutions within or adjacent to conserved amino acid motifs of penicillin-binding protein 2X in cephalosporin-resistant Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 43:1252–1255[PubMed]
    [Google Scholar]
  2. Boe L., Danielsen M., Knudsen S., Petersen J. B., Maymann J., Jensen P. R. 2000; The frequency of mutators in populations of Escherichia coli . Mutat Res 448:47–55 [View Article][PubMed]
    [Google Scholar]
  3. Chopra I., O’Neill A. J., Miller K. 2003; The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist Updat 6:137–145 [View Article][PubMed]
    [Google Scholar]
  4. Datsenko K. A., Wanner B. L. 2000; One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640–6645 [View Article][PubMed]
    [Google Scholar]
  5. Davies T. A., Shang W., Bush K., Flamm R. K. 2008; Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa . Antimicrob Agents Chemother 52:1510–1512 [View Article][PubMed]
    [Google Scholar]
  6. Denamur E., Bonacorsi S., Giraud A., Duriez P., Hilali F., Amorin C., Bingen E., Andremont A., Picard B. other authors 2002; High frequency of mutator strains among human uropathogenic Escherichia coli isolates. J Bacteriol 184:605–609 [View Article][PubMed]
    [Google Scholar]
  7. Grebe T., Hakenbeck R. 1996; Penicillin-binding proteins 2b and 2x of Streptococcus pneumoniae are primary resistance determinants for different classes of β-lactam antibiotics. Antimicrob Agents Chemother 40:829–834[PubMed]
    [Google Scholar]
  8. Hedge P. J., Spratt B. G. 1985; Amino acid substitutions that reduce the affinity of penicillin-binding protein 3 of Escherichia coli for cephalexin. Eur J Biochem 151:111–121 [View Article][PubMed]
    [Google Scholar]
  9. Horst J.-P., Wu T.-H., Marinus M. G. 1999; Escherichia coli mutator genes. Trends Microbiol 7:29–36 [View Article][PubMed]
    [Google Scholar]
  10. Jones R. N., Huynh H. K., Biedenbach D. J. 2004; Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 48:3136–3140 [View Article][PubMed]
    [Google Scholar]
  11. Koronakis V., Eswaran J., Hughes C. 2004; Structure and function of TolC: the bacterial exit duct for proteins and drugs. Annu Rev Biochem 73:467–489 [View Article][PubMed]
    [Google Scholar]
  12. Livermore D. M., Sefton A. M., Scott G. M. 2003; Properties and potential of ertapenem. J Antimicrob Chemother 52:331–344 [View Article][PubMed]
    [Google Scholar]
  13. Maciá M. D., Blanquer D., Togores B., Sauleda J., Pérez J. L., Oliver A. 2005; Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 49:3382–3386 [View Article][PubMed]
    [Google Scholar]
  14. Masuda N., Church G. M. 2002; Escherichia coli gene expression responsive to levels of the response regulator EvgA. J Bacteriol 184:6225–6234 [View Article][PubMed]
    [Google Scholar]
  15. Morero N. R., Monti M. R., Argaraña C. E. 2011; Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators. Antimicrob Agents Chemother 55:3668–3676 [View Article][PubMed]
    [Google Scholar]
  16. NCCLS 2003; Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, 6th edn. Approved standard M7–A6. Wayne, PA: National Committee for Clinical Laboratory Standards;
  17. Papp-Wallace K. M., Endimiani A., Taracila M. A., Bonomo R. A. 2011; Carbapenems: past, present, and future. Antimicrob Agents Chemother 55:4943–4960 [View Article][PubMed]
    [Google Scholar]
  18. Perry C. M., Ibbotson T. 2002; Biapenem. Drugs 62:2221–2234 [View Article][PubMed]
    [Google Scholar]
  19. Spratt B. G. 1978; Escherichia coli resistance to β-lactam antibiotics through a decrease in the affinity of a target for lethality. Nature 274:713–715 [View Article][PubMed]
    [Google Scholar]
  20. Sulavik M. C., Houseweart C., Cramer C., Jiwani N., Murgolo N., Greene J., DiDomenico B., Shaw K. J., Miller G. H. other authors 2001; Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother 45:1126–1136 [View Article][PubMed]
    [Google Scholar]
  21. Trong H. N., Prunier A. L., Leclercq R. 2005; Hypermutable and fluoroquinolone-resistant clinical isolates of Staphylococcus aureus . Antimicrob Agents Chemother 49:2098–2101 [View Article][PubMed]
    [Google Scholar]
  22. Tsuji M., Ishii Y., Ohno A., Miyazaki S., Yamaguchi K. 1998; In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 42:94–99[PubMed]
    [Google Scholar]
  23. Watson M. E. Jr, Burns J. L., Smith A. L. 2004; Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150:2947–2958 [View Article][PubMed]
    [Google Scholar]
  24. Yamada M., Watanabe T., Baba N., Takeuchi Y., Ohsawa F., Gomi S. 2008; Crystal structures of biapenem and tebipenem complexed with penicillin-binding proteins 2X and 1A from Streptococcus pneumoniae . Antimicrob Agents Chemother 52:2053–2060 [View Article][PubMed]
    [Google Scholar]
  25. Yang Y., Bhachech N., Bush K. 1995; Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. J Antimicrob Chemother 35:75–84 [View Article][PubMed]
    [Google Scholar]
  26. Zapun A., Contreras-Martel C., Vernet T. 2008; Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol Rev 32:361–385 [View Article][PubMed]
    [Google Scholar]
  27. Zgurskaya H. I., Krishnamoorthy G., Ntreh A., Lu S. 2011; Mechanism and function of the outer membrane channel TolC in multidrug resistance and physiology of enterobacteria. Front Microbiol 2:189[PubMed] [CrossRef]
    [Google Scholar]
  28. Zhanel G. G., Wiebe R., Dilay L., Thomson K., Rubinstein E., Hoban D. J., Noreddin A. M., Karlowsky J. A. 2007; Comparative review of the carbapenems. Drugs 67:1027–1052 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.051631-0
Loading
/content/journal/jmm/10.1099/jmm.0.051631-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error